🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme

RecruitingNAAges 50 Years - 69 YearsAllADVANCED MARKER DISCOVERY S.L.
NCT06696534 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are: * Values of experience of participants into screening programme. * Values of preferences of participants for screening methods. Participants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants ages from 50 to 69 years (both included) at the time of informed consent signed. * Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center. * Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form. Exclusion Criteria: * Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form. * Participants with a previous colonoscopy in consequence of a FOBT positive result. * Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.
💊

What it tests

  • Survey using a questionnaire.
  • Survey using a questionnaire.
📍

Where

2 sites
UCSP Sete Rios
Lisbon, Portugal
CS Mar Báltico
Madrid, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy